American journal of preventive cardiology最新文献

{"title":"From coronary calcium to heart failure risk: Expanding the role of CT in preventive cardiology","authors":"Sadeer Al-Kindi, Kershaw V. Patel","doi":"10.1016/j.ajpc.2026.101555","DOIUrl":"10.1016/j.ajpc.2026.101555","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101555"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disaggregating Asian cardiovascular phenotypes through cardiac CT adipose tissue imaging","authors":"Sadeer Al-Kindi , Khurram Nasir , Ron Blankstein","doi":"10.1016/j.ajpc.2026.101530","DOIUrl":"10.1016/j.ajpc.2026.101530","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101530"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidden in plain sight: AI-ECG triage in global telehealth networks","authors":"Partho P. Sengupta , Zakaria Almuwaqqat","doi":"10.1016/j.ajpc.2026.101540","DOIUrl":"10.1016/j.ajpc.2026.101540","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101540"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps in lipid screening and statin use among uninsured patients in a charitable community clinic","authors":"Tanvi A. Ingle , Christie Tran , Michael Pannell , Marcus Hurt , Josh Peedikayil , Laura Umana , Nora Gimpel , Amit Khera , Zahid Ahmad","doi":"10.1016/j.ajpc.2026.101603","DOIUrl":"10.1016/j.ajpc.2026.101603","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101603"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modifiable cardiovascular risk factors in people with polycystic ovarian syndrome (PCOS): Findings from the endocrine and mental health study","authors":"Alyssa M. Vela ,&nbsp;Maya Delity ,&nbsp;Rachel L. Johnson ,&nbsp;Lyndsey DuBose ,&nbsp;C. Neill Epperson ,&nbsp;Phoutdavone Phimphasone-Brady","doi":"10.1016/j.ajpc.2026.101528","DOIUrl":"10.1016/j.ajpc.2026.101528","url":null,"abstract":"<div><h3>Background</h3><div>Polycystic ovarian syndrome (PCOS) is a chronic multi-system condition, affecting up to 5 million reproductive aged females in the United States. Research points to significant cardiovascular (CV) risk burden among people with PCOS, even after controlling for body composition. This study sought to evaluate modifiable CV risk factors for a community sample of non-treatment seeking females with and without PCOS.</div></div><div><h3>Methods</h3><div>Participants completed validated surveys measuring depression, anxiety, sleep (insomnia, sleepiness, obstructive sleep apnea risk), and physical activity. PCOS status and body mass index (BMI) were self-reported. Data were summarized with descriptive statistics; linear regressions were used to assess differences between groups stratified by PCOS status and BMI category (above or below 25).</div></div><div><h3>Results</h3><div>Among 1,574 participants (95% identified as female, 72.7% White, 7% Black/African American, 7% Asian, mean age 30.6), 24% of participants with PCOS (N = 881) had a BMI &lt; 25, while 51% of non-PCOS participants’ BMI was normal or underweight. Independent of BMI, participants with self-reported PCOS indicated greater depression, anxiety, insomnia, and worse quality of life, compared to participants without PCOS. While PCOS status in those with BMI &gt; 25 was associated with higher sleep apnea risk, most PCOSxBMI interactions were nonsignificant, indicating no difference between BMI groups in the effect of PCOS on outcomes.</div></div><div><h3>Conclusions</h3><div>Regardless of BMI, people with PCOS report greater rates of modifiable psychosocial and behavioral CV risk factors. Given the multifactorial risk of PCOS for CV diseases, screening and treatment is essential for CV prevention in people with PCOS.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101528"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in post-discharge major adverse cardiovascular events following myocardial infarction: Insights from the veterans healthcare administration","authors":"Alexander T Sandhu ,&nbsp;Adam Furst ,&nbsp;Fatima Rodriguez ,&nbsp;Neil Kalwani ,&nbsp;David J. Maron ,&nbsp;Shriram Nallamshetty ,&nbsp;Natasha Din ,&nbsp;Michael Fan ,&nbsp;Kat Khachatourian ,&nbsp;Jeffrey R. Skaar ,&nbsp;Ivy Tonnu-Mihara","doi":"10.1016/j.ajpc.2026.101626","DOIUrl":"10.1016/j.ajpc.2026.101626","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101626"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zonal determinants of healthy aging: An exposomic analysis of determinants of healthy cardiovascular aging in Ohio","authors":"El Hussain Shamsa ,&nbsp;Sai Rahul Ponnana ,&nbsp;Santosh Siraspalli ,&nbsp;Zhuo Chen ,&nbsp;Jean-Eudes Dazard ,&nbsp;Alice T. Zhang ,&nbsp;Robert Okyere ,&nbsp;Tasveer Khawaja ,&nbsp;Kanimozhi Sivanantham ,&nbsp;Ian Neeland ,&nbsp;Salil Deo ,&nbsp;Sanjay Rajagopalan","doi":"10.1016/j.ajpc.2026.101517","DOIUrl":"10.1016/j.ajpc.2026.101517","url":null,"abstract":"<div><h3>Background</h3><div>Emerging evidence supports a role for social, behavioral, and environmental variables in explaining significant disparities in cardiovascular health and aging, beyond conventional risk factors.</div></div><div><h3>Objectives</h3><div>This study sought to identify and characterize regional “Healthy Aging” zones by identifying census-tract clusters with high rates of healthy coronary artery calcium (CAC) scores as a precison marker of cardiovascular aging in older populations.</div></div><div><h3>Methods</h3><div>In this prospective cohort study, 31,544 older patients (age ≥ 65) across 1,141 census tracts in Ohio enrolled in a no-charge CAC screening program (CLARIFY registry) were grouped as “healthy” (CAC = 0, n = 7,932) and “non-optimal” aging (CAC &gt; 0, n = 23,612). Cluster analysis was performed using Local Moran’s I on census-tracts and adjusted Z-scores of Local Moran’s I values were used to rank clusters from most significant “Non-optimal Aging” (low-low Moran’s I) to most significant “Healthy Aging” (high-high Moran’s I) zones. An eXtreme Gradient Boosting (XGBoost) model followed by SHAP (SHapley Additive exPlanations) analysis was used to determine the importance of 100 socioeconomic/environmental features in determining census-tract adjusted Z-scores.</div></div><div><h3>Results</h3><div>A total of 412 “High-High” and 356 “Low-Low” census-tracts were identified, which formed 4 distinct “Healthy Aging” clusters in northeast Ohio. “Healthy Aging” clusters were associated with less pollution, less noisy environments, lower rates of depression and disability, higher vegetation index, greater healthcare utilization, and greater economic/financial opportunity.</div></div><div><h3>Conclusions</h3><div>Our analysis implies geospatial clustering of healthy cardiovascular aging and provides evidence of a “healthy” census-tract phenotype, supporting the importance of exposomic factors in determining cardiovascular health.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101517"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development, structure, and implementation of cardiometabolic clinics in the United States, with a focus on comprehensive patient care","authors":"Jodeanna Sweeney ,&nbsp;Jason Liu ,&nbsp;Gregory Warren ,&nbsp;Alexander J. Blood","doi":"10.1016/j.ajpc.2026.101519","DOIUrl":"10.1016/j.ajpc.2026.101519","url":null,"abstract":"<div><div>Metabolic syndrome and associated cardiometabolic risk factors affect over one‑third of US adults, increasing the risk for atherosclerotic cardiovascular disease, type 2 diabetes, and chronic kidney disease. Recently termed cardiovascular-kidney-metabolic syndrome, the syndrome contributes to substantial clinical and economic burden. Despite guideline recommendations, affected patients who have multimorbidity often receive suboptimal, fragmented care. Cardiometabolic clinics (CMCs) comprise a multidisciplinary team that deliver comprehensive, preventive care to patients with cardiometabolic risk factors and diseases. This review outlines key considerations for the development, structure, and implementation of CMCs in the US. Initial steps include developing a financial model to demonstrate potential return on investment, defining the target patient population, establishing care delivery and operational plans, such as cost coverage evaluations, and leveraging digital solutions to improve access and engagement. The proposed CMC structure comprises a core team of a navigator and specialist in cardiometabolic diseases, based on two US-based models: the comprehensive care model and Cardiometabolic Center Alliance – Cardiometabolic Center of Excellence model. Training the team across cardiometabolic conditions is essential. Once established, demonstrating a positive return on investment can support expanding the team to additional specialties. Scalability remains crucial due to the rising prevalence of cardiovascular-kidney-metabolic syndrome. Studies show CMCs increase uptake of guideline-directed medical therapies and improve cardiometabolic outcomes, although larger, long-term studies are needed. Benefits also extend to healthcare providers, including improved communication, greater convenience, and reduced redundant tests and visits, supporting cost savings. CMCs can potentially reduce the clinical and economic burden of cardiovascular-kidney-metabolic syndrome in the US.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101519"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal cardiometabolic health and the role of GLP-1 receptor agonists from preconception to postpartum: A review of evidence and opportunities","authors":"Sumana Vardhan ,&nbsp;Clare Arnott ,&nbsp;Angela Xun-Nan Chen ,&nbsp;Antonina Frolova ,&nbsp;Raina Meka ,&nbsp;Nandini Raghuraman ,&nbsp;Aishwarya Vijay ,&nbsp;Sang Gune Yoo ,&nbsp;Zainab Mahmoud","doi":"10.1016/j.ajpc.2026.101471","DOIUrl":"10.1016/j.ajpc.2026.101471","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular disease (CVD) is a leading cause of maternal mortality. Adverse pregnancy outcomes (APOs), including preeclampsia and gestational diabetes, confer significant long-term cardiometabolic risk, yet prevention strategies during the preconception and postpartum periods are limited. Glucagon-like-peptide 1 receptor agonists and/or combined therapies (GLP-1 agonists) have demonstrated substantial benefits in weight reduction, glycemic and lipid control, and cardiovascular risk reduction in nonpregnant populations, but their impact on cardiometabolic health in women with increased risk of CVD during peripartum phases has not been defined.</div></div><div><h3>Content</h3><div>GLP-1 agonists are not approved for use during pregnancy or lactation; however, emerging evidence suggest a potential role in preconception weight optimization and postpartum metabolic recovery. This review highlights the mechanisms of GLP-1 agonists, evaluates available safety and efficacy data relevant to reproductive-age populations, and examines the potential application GLP-1 agonists during the preconception and postpartum periods, while also highlighting current clinical uncertainties.</div></div><div><h3>Summary</h3><div>GLP-1 agonists represent a promising preventive strategy for cardiometabolic risk reduction in women with increased risk of CVD. However, data specific to reproductive-age populations remain limited, leaving critical gaps regarding safety, efficacy, optimal timing of use, and implementation. Recognizing the preconception and postpartum periods as pivotal windows for CVD prevention underscores the need for focused research to guide evidence-based integration of effective interventions into preventative cardiovascular care for women.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101471"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial","authors":"Rosalynn Gill ,&nbsp;Meredith A. Carpenter ,&nbsp;Amy Holstein ,&nbsp;Ariadne Reyes Garcia ,&nbsp;Ayman Alkholder ,&nbsp;Aanchal Gupta ,&nbsp;Vatsala Singh ,&nbsp;Arshed A. Quyyumi ,&nbsp;Neda Rasouli ,&nbsp;Ian J. Neeland ,&nbsp;Stephen A. Williams","doi":"10.1016/j.ajpc.2026.101426","DOIUrl":"10.1016/j.ajpc.2026.101426","url":null,"abstract":"<div><h3>Background</h3><div>Cardioprotective (CP) therapies such as GLP-1 RA, SGLT2i, and PCSK9i medications remain underutilized in cardiovascular (CV) risk management. Individualized risk assessment using blood-based proteomic testing, such as Residual Cardiovascular Risk (RCVR) scores, may help guide treatment decisions.</div></div><div><h3>Objective</h3><div>To evaluate whether access to RCVR scores improves risk-concordant prescribing of CP medications in clinical practice.</div></div><div><h3>Methods</h3><div>In this multicenter, open label, behavioral randomized trial, adults with type 2 diabetes eligible for CP medications underwent SomaScan™ proteomic testing. Participants were randomized to an informed (RCVR results shared with patient and clinicians) or uninformed arm (results withheld until study end). CP prescribing rate and sensitivity-to-change of RCVR to CP initiation were assessed by trial arm. Chi-square trend in proportions, one-sided 2-sample tests for equality of proportions, and one-sided paired Wilcoxon signed-rank tests were used for statistical analysis.</div></div><div><h3>Results</h3><div>Among 377 baseline participants analyzed (59 % informed; mean age 66 ± 10.3 years; 45 % female), CP prescribing was significantly higher in the informed versus uninformed arm (32.1 % vs 9.6 %; OR 5.45; 95 % CI: 2.31–12.89; <em>p</em> &lt; 0.001); per-risk-bin rates were also significantly higher in all elevated risk bins (<em>p</em>&lt;0.05). Among 173 participants with paired RCVR scores from baseline-6-months, CP initiation (<em>n</em> = 24) in the informed arm (<em>n</em> = 92) corresponded to a 3.9 % reduction in proteomic-predicted CV risk (<em>p</em> = 0.036).</div></div><div><h3>Conclusions</h3><div>Disclosure of proteomic RCVR scores was associated with higher rates of CP prescribing and short-term reductions in proteomic risk scores among CP medication users; proteomics-based risk assessment may support personalized CV prevention.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101426"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}